• Explore /
  • Poster
  • / Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

Abstract Poster

Authors

null

Aly-Khan A. Lalani

Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada

Aly-Khan A. Lalani , Anand Swaminath , Gregory Russell Pond , Scott C. Morgan , Arun Azad , William Chu , Anil Kapoor , Michael Bonert , Jonathan L. Bramson , Michael G. Surette , Dominick Bosse , Shankar Siva , Georg A. Bjarnason , Darin Gopaul , Naveen S. Basappa , Jim Wright , Sebastien J. Hotte

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04090710

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS750)

DOI

10.1200/JCO.2023.41.6_suppl.TPS750

Abstract #

TPS750

Poster Bd #

N8

Abstract Disclosures

Similar Posters

First Author: Aly-Khan A. Lalani

First Author: Aly-Khan A. Lalani

First Author: Karie Runcie

First Author: Karie Runcie